Based on a positive pre-IND meeting with the U.S. FDA, Ceruvia Lifesciences has submitted an Investigation New Drug (IND) application to begin a Phase II clinical trial for the treatment of obsessive-compulsive disorder with psilocybin
Preliminary results from the Ceruvia funded pilot Phase II study taking place at Yale School of Medicine demonstrate rapid and robust improvement in OCD symptoms with a sustained effect.
Companies FeaturedCeruvia Lifesciences
Ceruvia Lifesciences are researching, developing and manufacturing novel psychedelic compounds for the treatment of hard-to-treat disorders including headache disorders and Obsessive Compulsive Disorder (OCD).
The Yale Psychedelic Science Group was established in 2016.